Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$0.75 - $1.26 $410,933 - $690,367
547,911 Added 41.2%
1,877,652 $1.41 Million
Q3 2023

Nov 14, 2023

BUY
$1.5 - $2.33 $169,650 - $263,523
113,100 Added 9.3%
1,329,741 $2 Million
Q2 2023

Aug 11, 2023

BUY
$0.68 - $1.59 $54,332 - $127,041
79,900 Added 7.03%
1,216,641 $1.93 Million
Q1 2023

May 12, 2023

BUY
$0.62 - $0.85 $38,750 - $53,125
62,500 Added 5.82%
1,136,741 $815,000
Q4 2022

Feb 13, 2023

SELL
$0.54 - $10.3 $23,868 - $455,260
-44,200 Reduced 3.95%
1,074,241 $623,000
Q3 2022

Nov 14, 2022

BUY
$0.96 - $9.68 $24,384 - $245,872
25,400 Added 2.32%
1,118,441 $1.06 Million
Q2 2022

Aug 12, 2022

BUY
$0.81 - $1.34 $564,246 - $933,444
696,600 Added 175.71%
1,093,041 $1.31 Million
Q1 2022

May 13, 2022

SELL
$1.23 - $1.95 $299,795 - $475,285
-243,736 Reduced 38.07%
396,441 $519,000
Q4 2021

Feb 11, 2022

SELL
$1.74 - $2.4 $811,884 - $1.12 Million
-466,600 Reduced 42.16%
640,177 $1.13 Million
Q3 2021

Nov 12, 2021

BUY
$2.08 - $3.6 $618,793 - $1.07 Million
297,497 Added 36.76%
1,106,777 $2.4 Million
Q2 2021

Aug 13, 2021

BUY
$3.36 - $10.56 $2.29 Million - $7.21 Million
682,703 Added 539.36%
809,280 $2.83 Million
Q1 2021

May 13, 2021

BUY
$9.26 - $14.36 $1.17 Million - $1.82 Million
126,577 New
126,577 $1.25 Million
Q4 2020

Feb 10, 2021

SELL
$9.84 - $14.26 $4.3 Million - $6.23 Million
-436,588 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$10.3 - $21.64 $1.51 Million - $3.17 Million
-146,360 Reduced 25.11%
436,588 $4.5 Million
Q2 2020

Aug 13, 2020

SELL
$8.53 - $25.64 $4.28 Million - $12.9 Million
-501,200 Reduced 46.23%
582,948 $12.2 Million
Q1 2020

May 14, 2020

SELL
$7.98 - $16.32 $2.97 Million - $6.07 Million
-371,700 Reduced 25.53%
1,084,148 $10.6 Million
Q4 2019

Feb 13, 2020

SELL
$5.12 - $12.22 $6.33 Million - $15.1 Million
-1,237,152 Reduced 45.94%
1,455,848 $16.8 Million
Q3 2019

Nov 13, 2019

SELL
$5.24 - $15.89 $6.1 Million - $18.5 Million
-1,164,500 Reduced 30.19%
2,693,000 $14.7 Million
Q2 2019

Aug 12, 2019

BUY
$5.1 - $11.89 $322,320 - $751,448
63,200 Added 1.67%
3,857,500 $45.9 Million
Q1 2019

May 14, 2019

BUY
$3.03 - $6.02 $231,894 - $460,728
76,533 Added 2.06%
3,794,300 $19.9 Million
Q4 2018

Feb 13, 2019

BUY
$2.87 - $5.92 $10.7 Million - $22 Million
3,717,767 New
3,717,767 $11.7 Million

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $681M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.